Hims & Hers Price Targets Cut to $25, $21 and $17 as Q4 EPS Falls to $0.08
Barclays lowered its price target on Hims & Hers to $25 from $48, while TD Cowen trimmed to $17 (Hold) and Morgan Stanley to $21 (Equal Weight), citing injectable GLP-1 regulatory risks. It posted Q4 EPS of $0.08 versus $0.19 consensus on $617.8M revenue with over 2.5 million subscribers.
1. Analyst Price Target Cuts
Barclays reduced its price target to $25 from $48 and maintained an Overweight rating. TD Cowen lowered its target to $17 with a Hold rating, and Morgan Stanley cut to $21 with an Equal Weight rating, each citing uncertainty around compounded injectable GLP-1 regulations and below-consensus EBITDA guidance.
2. Q4 Financial Results
Hims & Hers reported Q4 EPS of $0.08 versus the $0.19 consensus and revenue of $617.82 million versus $617.25 million expected. The company now serves over 2.5 million subscribers, with CEO Andrew Dudum highlighting platform growth and diversification efforts.
3. Platform Expansion and International Growth
In 2025 the company expanded its care offerings by launching labs testing, hormone therapies and diagnostics, and added menopause and testosterone services. It also entered the Canadian market to extend its consumer-first health platform internationally.